Drug Profile
Warfarin - Accu-Break Pharmaceuticals/Alembic Pharmaceuticals
Alternative Names: Accu-Break Warfarin Potassium; Accu-Break-formatted anticoagulantLatest Information Update: 20 Nov 2021
Price :
$50
*
At a glance
- Originator Accu-Break Pharmaceuticals
- Developer Accu-Break Pharmaceuticals; Alembic
- Class Anti-ischaemics; Anticoagulants; Coumarins
- Mechanism of Action Vitamin K antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Thromboembolism
Most Recent Events
- 07 Dec 2018 No development reported - Preregistration for Thromboembolism in USA (PO)
- 22 Nov 2015 Warfarin - Accu-Break Pharmaceuticals/Alembic Pharmaceuticals is available for licensing in USA, World as of 19 Nov 2015. www.accubreakpharmaceuticals.com
- 19 Nov 2015 Preregistration for Thromboembolism in USA (PO) before November 2015